The liver, which continuously filters blood circulating through the body, is also susceptible to "secondary" cancers, caused when tumours in other organs such as the colon, rectum, breast, head or neck have spread to the liver. These tumours are also known as liver metastases. The liver is the most common site of metastasis in patients with CRC. Approximately 50% of CRC patients will develop liver metastases during the course of the disease[vii].
About UCL
UCL (University College London) was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has over 39,000 students from 150 countries and over 12,500 staff. Our annual income is more than £1 billion
Ad Statistics
Times Displayed: 22234
Times Visited: 440 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About UCL Cancer Institute
The UCL Cancer Institute is a £40 million investment in central London based at University College London (UCL), one of the world's top universities and a founding member of the Crick Institute. UCL Cancer Institute draws together over 300 scientists working together to develop world-class basic and translational cancer research.
About the National Institute for Health Research
The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research.
Established by the Department of Health, the NIHR:
funds high quality research to improve health
trains and supports health researchers
provides world-class research facilities
works with the life sciences industry and charities to benefit all
involves patients and the public at every step
For further information, visit the NIHR website (http://www.nihr.ac.uk).
About BTG
BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges.
SOURCE BTG Plc
Back to HCB News
